Navigation Links
Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
Date:11/13/2008

STOCKHOLM, November 13 /PRNewswire/ -- Karolinska Development AB, a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science announced today the appointment of Dr. Carl Harald Janson as investment manager.

"Carl Harald is an outstanding addition to our management team," stated Conny Bogentoft, Chief Executive Officer of Karolinska Development. "His extensive experience within the medical, pharmaceutical and investment arenas will provide an invaluable perspective for our future growth". His former activities have included work as Medical Adviser for Clinical Research and Director of Immunology for Preclinical R&D at Astra Arcus AB, Senior Financial Analyst at Hagstromer & Qviberg Fondkommission AB and Danske Securities, Danske Bank in Stockholm. He moved into fund management with companies including Carnegie Investment Bank AB.

He is a Medical Doctor holding a PhD. from Karolinska Institutet in Stockholm and qualified as a Certified European Financial Analyst at Stockholm School of Economics.

Carl Harald will take responsibility for the Karolinska Development pharma project portfolio. Bringing with him a vast network of individuals with both management and operational skills, which will further strengthen the cost effective business model used by Karolinska Development.

About Karolinska Development

Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Sweden http://www.karolinskadevelopment.com
More about Karolinska Development: http://www.karolinskadevelopment.com

Contact: Conny Bogentoft, CEO

Tel: +46(0)8-524861-43

e-mail: info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... YORK , May 19, 2016 ... space will fully recover given the relentless pressures in ... for sure in the investors circle though - numerous ... due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four names ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ...
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
Breaking Biology Technology:
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
Breaking Biology News(10 mins):